Global intrassacular embolization systems market demand is anticipated to be valued at USD 2,920.44 Million in 2022, forecast to grow at a CAGR of 7.2% to be valued at USD 5,861.41 Million from 2022 to 2032. The demand is expected to soar up in East Asia owing to the recent surge in healthcare standards in emerging countries like Japan and China.
| Report Attribute | Details |
|---|---|
| Estimated Base Year Value (2021) | USD 2,715 Million |
| Expected Market Value (2022) | USD 2,920.44 Million |
| Anticipated Forecast Value (2032) | USD 5,861.41 Million |
| Projected Growth Rate (2022 to 2032) | 7.2% CAGR |
An aneurysm occurs when a section of an artery wall weakens, allowing it to balloon out or widen abnormally. A stroke, blood clots, and increased intracranial pressure can all result from a bleed. Intrasaccular Embolization Systems typically involve restricting blood flow in an aneurysm that has formed.
Intrassacular Embolization Systems are surgical interventions that are used to fill aneurysms. Typically, an embolic coil is inserted into the aneurysms and blood platelets in the brain are restricted. The Intrasaccular Embolization Systems promote rapid clotting and the prevention of further brain damage. The use of preventive stenting by Intrasaccular Embolization Systems reduces the risk of surgical intervention in adjacent parts of the brain.
Furthermore, endovascular repair is used to achieve hemostasis. The time required to receive the Intrasaccular Embolization procedure is critical to the survival of patients with intracranial aneurysms. The Intrasaccular Embolization System provides a significant advantage in terms of patient recovery.
The rising incidence of brain aneurysms is a major driving factor for the Intrasaccular Embolization Systems market, owing to the rising burden of chronic diseases. Aneurysms account for approximately 10-12% of stroke cases, according to the American Brain Aneurysm Foundation.
Whereas approximately 10% to 14% of people suffer from intracranial bleeding, which results in death. The market for Intrasaccular Embolization Systems is being driven by an increase in new cases of venous diseases. Furthermore, the increased use of antihypertensive drugs raises the risk of intracranial aneurysms, increasing the demand for Intrasaccular Embolization Systems.
The main advantage of a device-based Intrasaccular Embolization System is its quick action and reduced recovery time, which in the case of intracranial aneurysms results in the patient's well-being. The shorter onset of action of a coil or WEB system is expected to boost the market for Intrasaccular Embolization Systems.
The increasing prescription rate of antihypertensive drugs by physicians and the high clinical effectiveness of Intrasaccular Embolization Systems are expected to expand the market for Intrasaccular Embolization System.
The increased use of venous dilators, combined with an increase in the number of patients with high blood pressure, is expected to increase the risk of aneurysms and stroke, propelling the market for Intrasaccular Embolization Systems.
Rigid regulatory guidelines for devices used in Intrasaccular Embolization Systems, combined with the high cost of the procedure,are expected to limit the global Intrasaccular Embolization Systems Market's growth.
Because of higher technological advancement and recent FDA approvals for WEB systems, North America is expected to be the dominant market in the global intrasaccular embolization systems market during the forecast period.
According to Future Market Insights, Europe is expected to provide immense growth opportunities for Intrasaccular Embolization Systems Market. Extensive applications in the health industry are keeping sales of Intrasaccular Embolization Systems Market afloat across the region.
Europe is generating high demand for Intrasaccular Embolization Systems Market, as these regions are witnessing an uptick in construction activity. Moreover, the chemical industry in these countries is also experiencing a major upsurge, which will generate favorable conditions for market growth.
The global market for Intrasaccular Embolization Systems is fragmented with large number of market players. Examples of some of the primary key players operating in the global Intrasaccular Embolization Systems market are MicroVention, Inc., Medtronic Plc., Stryker Corporation, Cook Medical, dePuySynthes, Kaneka Pharmaceuticals, Penubbra and Braile Biomedica among others.
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 5.2% from 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2015 to 2020 |
| Forecast Period | 2022 to 2032 |
| Quantitative Units | Revenue in USD Billion, Volume in Kilotons and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Product Type, End User, Region |
| Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA , Canada, Brazil, Argentina, Chile, Peru, Germany, UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, ASEAN, GCC, South Africa, Turkey, Iran, Israel |
| Key Companies Profiled | MicroVention, Inc.; Medtronic Plc.; Stryker Corporation; Cook Medical; dePuySynthes; Kaneka Pharmaceuticals; Penubbra; Braile Biomedica |
| Customization | Available Upon Request |
FMI projects the global Intrasaccular Embolization Systems Market to expand at a 7.2% value CAGR by 2032
North America is expected to be the most opportunistic Intrasaccular Embolization Systems Market.
MicroVention, Inc., Medtronic Plc. and stryker are some prominent Intrasaccular Embolization Systems Market manufacturers
Explore Similar Insights
Intrasaccular Embolization Systems Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
